Of the pathways that were differentially regulated we identified IL13 signaling as uniquely upregulated in LECs from individuals with end-stage NASH (Figure 5 and Supplementary Table 2). This evidence concerns the gene IL13 and metabolic dysfunction-associated steatohepatitis.